Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Initiates Development of Novel, Versatile Vaccine Adjuvant
June 12, 2014
- Nippon Shinyaku to Concentrate Sales Force in Three Therapeutic Fields
June 11, 2014
- PII Study of Novel AD Treatment Begins in Japan: Fujifilm Holdings
June 11, 2014
- Novartis Pharma Collects Adverse Events of 10,000 Patients in Wake of Unreported ADRs in SIGN Trial
June 10, 2014
- Nippon Kayaku to Deploy RA Reps for Remicade Biosimilar
June 9, 2014
- April Ethical Drug Sales Down 3.5%, Hurt by Pullback from Pre-Tax Hike Demand: Crecon Report
June 9, 2014
- Results from PI/PII Studies of BBI608, BBI503 Presented at ASCO Annual Meeting: DSP
June 9, 2014
- AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
- Malignant STS Treatment Trabectedin Achieves Primary Endpoint in Domestic PII Clinical Trial: Taiho
June 6, 2014
- Nihon Chouzai to Provide Online Daily Pharmacy Prescription Trend Info.
June 6, 2014
- Combination Therapy of Avastin, Tarceva Significantly Prolongs PFS in PII Study: Roche
June 6, 2014
- Sales of 26 Pharma Companies Up 10.3% Driven by Strong Overseas Sales
June 5, 2014
- Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
- Sysmex Inostics, Merck Serono of Germany to Codevelop CoDx for Erbitux for Treatment of Colon Cancer
June 5, 2014
- Eisai’s Halaven Extends OS in Metastatic Breast Cancer Patients
June 4, 2014
- Taiho’s TS-1 Able to Prolong Life for Metastatic, Relapsed Breast Cancer Patients
June 4, 2014
- Shionogi Establishes Wholly Owned Subsidiary in Singapore as Foothold for Development and Marketing in ASEAN States
June 4, 2014
- Nexavar Fails to Show Efficacy in Adjuvant Therapy for Liver Cancer: Bayer Yakuhin
June 4, 2014
- Eisai’s Anticancer Agent Lenvatinib Significantly Extends PFS in PIII Study
June 3, 2014
- Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…